Seventy-nine ( 95.2 % ) subjects in the HBOC-201 group and 72 ( 93.5 % ) in the RBC group experienced adverse events ( AEs ) , judged to be associated with study treatment in 59 ( 71.1 % ) and 18 ( 23.4 % ) subjects , respectively .